Replies to post #226016 on Amarin Corp Plc (AMRN)

[BioChica]

I think J.L. can word primary prevention class better than me. Primary prevention trails are tough, it's about screening people from the population that are at risk for a heart attack. I believe the Jupiter Trail did well because they went after a population with high inflammation, as we should do in the future. Perhaps screening patients for multiple inflammatory markers.

There is no doubt, that this drug would have a positive effect on primary prevention. It's up to the FDA to sort through the data and make a sound scientific decision.

P.S. Why we are excited to see the result of EVAPORATE trial later this week to be made public at the AHA meeting.